3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDIV
1
Study Type
Interventional
23
Observational
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Urinary Bladder Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
Surveys and Questionnaires
34
Blood Specimen Collection
24
enzalutamide
18
Radiotherapy
15
Docetaxel
15
Biopsy
14
Abiraterone Acetate
14
apalutamide
13
Leuprolide
13
Interviews as Topic
13
Observation
12
Magnetic Resonance Spectroscopy
12
Watchful Waiting
10
radium Ra 223 dichloride
9
darolutamide
9
Androgen Antagonists
9
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
8
Radiosurgery
7
Magnetic Resonance Imaging
7
Brachytherapy
7
abiraterone
6
Specimen Handling
6
Amplified Fragment Length Polymorphism Analysis
6
Triptorelin Pamoate
5
Standard of Care
5
Positron Emission Tomography Computed Tomography
5
Gonadotropin-Releasing Hormone
5
Focus Groups
5
Registries
4
Radiotherapy, Intensity-Modulated
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Prostatic Neoplasms
×
sargramostim
×
Clear all
NCT03695835
2020-07-22
NIRPA
Gary Onik MD
Completed
27 enrolled